1. Academic Validation
  2. Dendritic cell-liposome conjugates reverse immunosuppressive tumor microenvironment for inhibiting colitis-associated colorectal cancer

Dendritic cell-liposome conjugates reverse immunosuppressive tumor microenvironment for inhibiting colitis-associated colorectal cancer

  • Acta Pharmacol Sin. 2025 Aug 8. doi: 10.1038/s41401-025-01614-7.
Wen-Zhe Yi # 1 2 Xin-di Qian # 1 3 Xiao-Xuan Xu 1 2 Rong Pu 4 Dan Yan 1 Zhi-Wen Zhao 1 2 Ya-Ping Li 5 6 7 8 Dang-Ge Wang 9
Affiliations

Affiliations

  • 1 State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • 2 University of Chinese Academy of Sciences, Beijing, 100049, China.
  • 3 Department of Medical Ultrasound and Center of Minimally Invasive Treatment for Tumor, Shanghai Tenth People's Hospital, Ultrasound Research and Education Institute, School of Medicine Tongji University, Shanghai, 200072, China.
  • 4 Nanjing University of Chinese Medicine, Nanjing, 210023, China.
  • 5 State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. ypli@simm.ac.cn.
  • 6 University of Chinese Academy of Sciences, Beijing, 100049, China. ypli@simm.ac.cn.
  • 7 Nanjing University of Chinese Medicine, Nanjing, 210023, China. ypli@simm.ac.cn.
  • 8 Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, 264000, China. ypli@simm.ac.cn.
  • 9 Precision Research Center for Refractory Diseases, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 201620, China. dg_wang@sjtu.edu.cn.
  • # Contributed equally.
Abstract

The progression of colitis-associated Cancer (CAC) is strongly associated with bone marrow-derived immunosuppressive cells (MDSCs). Although CAC could be suppressed by inducing MDSCs Apoptosis, the immunosuppressive tumor microenvironment (TME) maintains immune homeostasis by upregulating M2-type tumor-associated macrophages (TAMs), thus leading to adaptive immune tolerance. Herein, we develop a dendritic cell (DC)-liposome conjugate to reverse immunosuppressive TME, showing remarkable efficiency against colorectal Cancer. The DC-liposome conjugate is fabricated by conjugating resolvin E1-loaded liposomes with Fas ligand-transfected DCs, which eliminates tumor-infiltrated Fas+ MDSCs and enhances TAM phagocytosis in tumors. It shows significant therapeutic effects in preclinical CAC models and alleviates severe colitis when combined with immune checkpoint inhibitors. This study provides a feasible and customized cell-drug conjugate to overcome immunosuppressive TME for enhancing CAC immunotherapy.

Keywords

colitis-associated cancer; dendritic cell; liposome; marrow-derived immunosuppressive cell; tumor-associated macrophage.

Figures
Products